Srm Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 30-12-2024
- Paid Up Capital ₹ 0.10 M
as on 30-12-2024
- Company Age 16 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -12.33%
(FY 2023)
- Ebitda -64.29%
(FY 2023)
- Net Worth -9.08%
(FY 2023)
- Total Assets -18.39%
(FY 2023)
About Srm Pharmaceuticals (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pachamuthu Ravi and Viswaprakash serve as directors at the Company.
- CIN/LLPIN
U33110TN2008PTC069469
- Company No.
069469
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Oct 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Srm Pharmaceuticals (India)?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pachamuthu Ravi  | Director | 06-Oct-2008 | Current |
| Viswaprakash | Director | 12-Apr-2024 | Current |
Financial Performance of Srm Pharmaceuticals (India).
Srm Pharmaceuticals (India) Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 12.33% decrease in profit. The company's net worth dipped by a decrease of 9.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srm Pharmaceuticals (India)?
Unlock access to Srm Pharmaceuticals (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Surya-Global Infrastructure & Facilities Management LlpActive 2 years 5 months
Pachamuthu Ravi is a mutual person
- Srm Engineering Construction Corporation LimitedActive 29 years 3 months
Pachamuthu Ravi is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Srm Pharmaceuticals (India)?
Unlock and access historical data on people associated with Srm Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srm Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srm Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
